Despite the success in correlating O-6-methylguanine-DNA-methyltransferase (MGMT) methylation with survival in glioblastoma patients treated with alkylating agents [19], the clinical utility of other biomarkers is limited. This evidence concerns the gene MGMT and glioblastoma.